{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:36:21Z","timestamp":1791765381108,"version":"4.3.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejves.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Vascular and Endovascular Surgery"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejvs.2025.08.035","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T01:55:40Z","timestamp":1755741340000},"page":"448-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pre-operative Cilostazol in Patients with Chronic Limb Threatening Ischaemia Associated with Improved Survival after Endovascular Revascularisation"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9925-9634","authenticated-orcid":false,"given":"Alexandra A.","family":"Sansosti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Aljabban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.X.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virendra I.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejvs.2025.08.035_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/0272989X0202200208","article-title":"Peripheral arterial occlusive disease: prognostic value of signs, symptoms, and the ankle-brachial pressure index","volume":"22","author":"Hooi","year":"2002","journal-title":"Med Decis Making"},{"key":"10.1016\/j.ejvs.2025.08.035_bib2","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery isease: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"issue":"6S","key":"10.1016\/j.ejvs.2025.08.035_bib3","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"69","author":"Conte","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJMcp1709326","article-title":"Chronic limb-threatening ischemia","volume":"379","author":"Farber","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejvs.2025.08.035_bib5","first-page":"e686","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ejvs.2025.08.035_bib6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejvs.2020.11.009","article-title":"Comparison of long term outcomes after endovascular treatment versus bypass surgery in chronic limb threatening ischaemia patients with long femoropopliteal lesions","volume":"61","author":"Zlatanovic","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib7","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0140-6736(05)67704-5","article-title":"Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial","volume":"366","author":"Adam","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejvs.2025.08.035_bib8","first-page":"1144","article-title":"Effect of cilostazol on platelet aggregation and experimental thrombosis","volume":"35","author":"Kimura","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejvs.2025.08.035_bib9","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIRCRESAHA.121.318258","article-title":"Contemporary medical management of peripheral artery disease","volume":"128","author":"Bonaca","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.ejvs.2025.08.035_bib10","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1046\/j.1532-5415.2002.50604.x","article-title":"Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials","volume":"50","author":"Regensteiner","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ejvs.2025.08.035_bib11","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/s41588-018-0222-9","article-title":"Genetics of blood lipids among \u223c300,000 multi-ethnic participants of the Million Veteran Program","volume":"50","author":"Klarin","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejvs.2025.08.035_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jacc.2008.09.020","article-title":"Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication","volume":"53","author":"Soga","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejvs.2025.08.035_bib13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1358863X19838327","article-title":"Outcomes with cilostazol after endovascular therapy of peripheral artery disease","volume":"24","author":"Megaly","year":"2019","journal-title":"Vasc Med"},{"key":"10.1016\/j.ejvs.2025.08.035_bib14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jvs.2016.10.098","article-title":"Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease","volume":"65","author":"Zen","year":"2017","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00210-022-02233-3","article-title":"Cilostazol attenuates cardiac oxidative stress and inflammation in hypercholesterolemic rats","volume":"395","author":"de Oliveira","year":"2022","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejvs.2025.08.035_bib16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.21470\/1678-9741-2020-0651","article-title":"Cardioprotective effect of cilostazol on ischemia-reperfusion injury model","volume":"37","author":"Sahin","year":"2022","journal-title":"Braz J Cardiovasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/FJC.0000000000001276","article-title":"Cardiovascular protection associated with cilostazol, colchicine, and target of rapamycin inhibitors","volume":"80","author":"Adeva-Andany","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejvs.2025.08.035_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jstrokecerebrovasdis.2007.12.005","article-title":"Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication","volume":"17","author":"Stone","year":"2008","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.ejvs.2025.08.035_bib19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvs.2007.10.009","article-title":"Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects)","volume":"47","author":"Hiatt","year":"2008","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib20","first-page":"CD003748","article-title":"Cilostazol for intermittent claudication","volume":"6","author":"Brown","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejvs.2025.08.035_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejvs.2023.08.067","article-title":"Editor's Choice \u2013 European Society for Vascular Surgery (ESVS) 2024 clinical practice guidelines on the management of asymptomatic lower limb peripheral arterial disease and intermittent claudication","volume":"67","author":"Nordanstig","year":"2024","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejvs.2023.03.042","article-title":"Editor's Choice \u2013 European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases","volume":"65","author":"Twine","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.avsg.2023.12.071","article-title":"The use and impact of cilostazol on patients undergoing endovascular peripheral interventions","volume":"103","author":"Alameddine","year":"2024","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jvs.2024.01.010","article-title":"The effect of cilostazol on late outcomes after endovascular treatment for occlusive femoropopliteal disease","volume":"80","author":"Galyfos","year":"2024","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0314957","article-title":"The drug risks of cilostazol: a pharmacovigilance study of FDA Adverse Event Reporting System database","volume":"19","author":"Peng","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejvs.2025.08.035_bib26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrneph.2013.143","article-title":"The applicability of eGFR equations to different populations","volume":"9","author":"Delanaye","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ejvs.2025.08.035_bib27","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJMoa2103753","article-title":"Race, genetic ancestry, and estimating kidney function in CKD","volume":"385","author":"Hsu","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejvs.2025.08.035_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.thromres.2014.05.040","article-title":"Cilostazol and outcome in outpatients with peripheral artery disease","volume":"134","author":"Perez","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejvs.2025.08.035_bib29","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jvs.2008.11.098","article-title":"The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease","volume":"49","author":"O'Donnell","year":"2009","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib30","article-title":"Cilostazol induces eNOS and TM expression via activation with sirtuin 1\/Kr\u00fcppel-like factor 2 pathway in endothelial cells","volume":"22","author":"Wu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejvs.2025.08.035_bib31","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.5551\/jat.32912","article-title":"The effect of cilostazol on endothelial function as assessed by flow-mediated dilation in patients with coronary artery disease","volume":"23","author":"Mori","year":"2016","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ejvs.2025.08.035_bib32","first-page":"44","article-title":"Balloon angioplasty plus cilostazol administration versus primary stenting of small coronary artery disease: final results of COMPASS","volume":"63","author":"Tsuchikane","year":"2004","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ejvs.2025.08.035_bib33","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/dom.13667","article-title":"Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study","volume":"21","author":"Lee","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ejvs.2025.08.035_bib34","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/1753-0407.13300","article-title":"Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: long-term follow-up of the ESCAPE study","volume":"14","author":"Sohn","year":"2022","journal-title":"J Diabetes"},{"key":"10.1016\/j.ejvs.2025.08.035_bib35","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.3390\/ijms25052593","article-title":"The role of cilostazol, a phosphodiesterase-3 inhibitor, in the development of atherosclerosis and vascular biology: a review with meta-analysis","volume":"25","author":"Sohn","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejvs.2025.08.035_bib36","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/0003319720980619","article-title":"Evaluation of clinical outcomes after revascularization in patients with chronic limb-threatening ischemia: results from a prospective national cohort study (RIVALUTANDO)","volume":"72","author":"de Donato","year":"2021","journal-title":"Angiology"},{"key":"10.1016\/j.ejvs.2025.08.035_bib37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jvs.2008.02.062","article-title":"Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions","volume":"48","author":"Iida","year":"2008","journal-title":"J Vasc Surg"},{"issue":"Suppl. S","key":"10.1016\/j.ejvs.2025.08.035_bib38","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib39","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.jvs.2015.07.065","article-title":"The natural history of untreated severe or critical limb ischemia","volume":"62","author":"Abu Dabrh","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib40","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa2207899","article-title":"Surgery or endovascular therapy for chronic limb-threatening ischemia","volume":"387","author":"Farber","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejvs.2025.08.035_bib41","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jvs.2020.08.125","article-title":"Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization","volume":"73","author":"Desai","year":"2021","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ejvs.2012.09.020","article-title":"Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia","volume":"44","author":"Soga","year":"2012","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ejvs.2025.08.035_bib43","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jvs.2017.03.416","article-title":"Adherence to lipid management guidelines is associated with lower mortality and major adverse limb events in patients undergoing revascularization for chronic limb-threatening ischemia","volume":"66","author":"O'Donnell","year":"2017","journal-title":"J Vasc Surg"}],"container-title":["European Journal of Vascular and Endovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078588425007932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078588425007932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:45:34Z","timestamp":1773099934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078588425007932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1078588425007932"],"URL":"https:\/\/doi.org\/10.1016\/j.ejvs.2025.08.035","relation":{},"ISSN":["1078-5884"],"issn-type":[{"value":"1078-5884","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-operative Cilostazol in Patients with Chronic Limb Threatening Ischaemia Associated with Improved Survival after Endovascular Revascularisation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Vascular and Endovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejvs.2025.08.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society for Vascular Surgery. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}